Efficacy of lenvatinib plus pembrolizumab in hepatocellular carcinoma with metachronous lung metastasis: a report of two cases
Introduction: Immune checkpoint inhibitors (ICIs) and a combination of ICIs with targeted antiangiogenic agents are effective in treatment of advanced hepatocellular carcinoma (HCC). Studies have not explored effective biomarkers for prediction of HCC sensitivity to immunotherapy. Case description:...
Saved in:
| Published in: | Tumori Vol. 107; no. 6; pp. NP114 - NP119 |
|---|---|
| Main Authors: | , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
London, England
SAGE Publications
01-12-2021
|
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Introduction:
Immune checkpoint inhibitors (ICIs) and a combination of ICIs with targeted antiangiogenic agents are effective in treatment of advanced hepatocellular carcinoma (HCC). Studies have not explored effective biomarkers for prediction of HCC sensitivity to immunotherapy.
Case description:
The current study explored two consecutive patients with HCC with metachronous lung metastasis who were treated with lenvatinib and pembrolizumab as first-line treatment and third-line treatment, respectively. The two cases showed significant tumor shrinkage and long progression-free survival (>19 months and 12 months, respectively).
Conclusions:
The findings of the current study and recently published data indicate lung metastasis as a potential clinical therapeutic indicator for efficacy of immunotherapy against HCC. |
|---|---|
| AbstractList | Introduction:
Immune checkpoint inhibitors (ICIs) and a combination of ICIs with targeted antiangiogenic agents are effective in treatment of advanced hepatocellular carcinoma (HCC). Studies have not explored effective biomarkers for prediction of HCC sensitivity to immunotherapy.
Case description:
The current study explored two consecutive patients with HCC with metachronous lung metastasis who were treated with lenvatinib and pembrolizumab as first-line treatment and third-line treatment, respectively. The two cases showed significant tumor shrinkage and long progression-free survival (>19 months and 12 months, respectively).
Conclusions:
The findings of the current study and recently published data indicate lung metastasis as a potential clinical therapeutic indicator for efficacy of immunotherapy against HCC. INTRODUCTIONImmune checkpoint inhibitors (ICIs) and a combination of ICIs with targeted antiangiogenic agents are effective in treatment of advanced hepatocellular carcinoma (HCC). Studies have not explored effective biomarkers for prediction of HCC sensitivity to immunotherapy. CASE DESCRIPTIONThe current study explored two consecutive patients with HCC with metachronous lung metastasis who were treated with lenvatinib and pembrolizumab as first-line treatment and third-line treatment, respectively. The two cases showed significant tumor shrinkage and long progression-free survival (>19 months and 12 months, respectively). CONCLUSIONSThe findings of the current study and recently published data indicate lung metastasis as a potential clinical therapeutic indicator for efficacy of immunotherapy against HCC. Immune checkpoint inhibitors (ICIs) and a combination of ICIs with targeted antiangiogenic agents are effective in treatment of advanced hepatocellular carcinoma (HCC). Studies have not explored effective biomarkers for prediction of HCC sensitivity to immunotherapy. The current study explored two consecutive patients with HCC with metachronous lung metastasis who were treated with lenvatinib and pembrolizumab as first-line treatment and third-line treatment, respectively. The two cases showed significant tumor shrinkage and long progression-free survival (>19 months and 12 months, respectively). The findings of the current study and recently published data indicate lung metastasis as a potential clinical therapeutic indicator for efficacy of immunotherapy against HCC. |
| Author | Li, JieLang Chen, Ting Yang, Yu Bi, Feng |
| Author_xml | – sequence: 1 givenname: JieLang surname: Li fullname: Li, JieLang organization: Department of Abdominal Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China – sequence: 2 givenname: Ting surname: Chen fullname: Chen, Ting organization: Department of Abdominal Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China – sequence: 3 givenname: Feng surname: Bi fullname: Bi, Feng organization: Department of Abdominal Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China – sequence: 4 givenname: Yu orcidid: 0000-0002-3853-7028 surname: Yang fullname: Yang, Yu email: yangyu@wchscu.cn organization: Department of Abdominal Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34296632$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9UMtKxEAQHGRF19UP8CJz9BKdRyYPb7KsDxC86Dl0Jh13JJmJM4myHvx2E1e9CEJDQ3dVdVcdkJl1Fgk55uyM8zQ9Z5KxLOeJ4JxJKZXcIXPBZBYJJfIZmU_7aALsk4MQnhmLmUiSPbIvY5EniRRz8rGqa6NBb6iraYP2FXpjTUm7Zgi0w7b0rjHvQwslNZausYPeaWyaoQFPNXhtrGuBvpl-TVvsQa-9s27kNoN9-pqEsUy4oEA9ds7306H-zY3kgOGQ7NbQBDz67gvyeLV6WN5Ed_fXt8vLu0jLmPURpixXwDWLhU40QAw8RsEqiVmlUiizOpNliaBKplKpKq55FQNUmKZCQ45yQU63up13LwOGvmhNmHyAxfHbQiilOIvlmN6C8C1UexeCx7rovGnBbwrOiin24k_sI-fkW34oW6x-GT85j4CzLSDAExbPbvB2tPuP4ie7tI8o |
| CitedBy_id | crossref_primary_10_3389_fonc_2022_879454 |
| Cites_doi | 10.1056/NEJMoa1915745 10.1158/2326-6066.CIR-16-0325 10.1200/JCO.20.00808 10.1002/hep.25956 10.3390/cancers13020213 10.1038/bjc.2016.308 10.1159/000501275 10.1038/s41591-018-0045-3 |
| ContentType | Journal Article |
| Copyright | Fondazione IRCCS Istituto Nazionale dei Tumori 2021 |
| Copyright_xml | – notice: Fondazione IRCCS Istituto Nazionale dei Tumori 2021 |
| DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
| DOI | 10.1177/03008916211033353 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: ECM name: MEDLINE url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2038-2529 |
| EndPage | NP119 |
| ExternalDocumentID | 10_1177_03008916211033353 34296632 10.1177_03008916211033353 |
| Genre | Journal Article Case Reports |
| GroupedDBID | --- -TM 0R~ 123 2WC 53G 54M 5RE 5Z9 AABMB AACMV AADUE AAEWN AAGGD AAHPS AAJQC AAKGS AAPEO AARIX AATAA AAZBJ ABCCA ABDWY ABFWQ ABJNI ABKRH ABLUO ABPNF ABRHV ABVFX ABYTW ACARO ACDXX ACFEJ ACFMA ACGBL ACGFS ACLFY ACLHI ACOFE ACOXC ACROE ACSIQ ACUAV ACUIR ACVIN ACXKE ACXMB ADBBV ADEIA ADMPF ADRRZ ADUKL AENEX AESZF AEWDL AEWHI AEXNY AFKRG AFMOU AFQAA AFUIA AGKLV AGNHF AIEWD AIGRN AIOMO AJEFB AJMMQ AJUZI AJXAJ AKSRI ALMA_UNASSIGNED_HOLDINGS ALTZF ANDLU ARTOV B8M BBRGL BDDNI BKIIM BKSCU BPACV BSEHC BWJAD CBRKF CDWPY CFDXU CORYS CQQTX CUTAK DC- DOPDO DV7 EBS EJD F5P FHBDP GROUPED_SAGE_PREMIER_JOURNAL_COLLECTION GX1 J8X JCYGO K.F M4V O0M OVD Q1R SAFTQ SCNPE SFC SHG SPQ SPV TEORI UDS UGK ZGI ZONMY ZPPRI ZRKOI ZSSAH ~31 ACJER ALKWR CGR CUY CVF ECM EIF H13 NPM AAYXX ADVBO CITATION 7X8 |
| ID | FETCH-LOGICAL-c340t-e7095a1c042c6caa4a14e20d3e8d57ab8f83bbea5b05735d1c1d4aade772ca9e3 |
| IEDL.DBID | ARPSY |
| ISSN | 0300-8916 |
| IngestDate | Fri Oct 25 00:53:43 EDT 2024 Fri Nov 22 01:47:19 EST 2024 Sat Sep 28 08:23:12 EDT 2024 Tue Jul 16 20:41:52 EDT 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Keywords | targeted therapy Hepatocellular carcinoma PD-1 immunotherapy |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c340t-e7095a1c042c6caa4a14e20d3e8d57ab8f83bbea5b05735d1c1d4aade772ca9e3 |
| Notes | ObjectType-Case Study-2 SourceType-Scholarly Journals-1 ObjectType-Feature-4 content type line 23 ObjectType-Report-1 ObjectType-Article-3 |
| ORCID | 0000-0002-3853-7028 |
| PMID | 34296632 |
| PQID | 2555104320 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2555104320 crossref_primary_10_1177_03008916211033353 pubmed_primary_34296632 sage_journals_10_1177_03008916211033353 |
| PublicationCentury | 2000 |
| PublicationDate | 20211200 2021-Dec 2021-12-00 20211201 |
| PublicationDateYYYYMMDD | 2021-12-01 |
| PublicationDate_xml | – month: 12 year: 2021 text: 20211200 |
| PublicationDecade | 2020 |
| PublicationPlace | London, England |
| PublicationPlace_xml | – name: London, England – name: United States |
| PublicationTitle | Tumori |
| PublicationTitleAlternate | Tumori |
| PublicationYear | 2021 |
| Publisher | SAGE Publications |
| Publisher_xml | – name: SAGE Publications |
| References | Rapposelli, De Matteis, Lanuti 2021; 13 Finn, Qin, Ikeda 2020; 382 Kim, Hong, Cheon 2020 Arao, Ueshima, Matsumoto 2013; 57 Finn, Ikeda, Zhu 2020; 38 Tumeh, Hellmann, Hamid 2017; 5 Khoja, Kibiro, Metser 2016; 115 Guo, Han, Liu 2015; 8 Lu, Hsu, Shao 2019; 8 Guo, Zhang, Zheng 2018; 24 bibr9-03008916211033353 bibr4-03008916211033353 Kim HS (bibr6-03008916211033353) 2020 bibr7-03008916211033353 bibr3-03008916211033353 Guo F (bibr10-03008916211033353) 2015; 8 bibr1-03008916211033353 bibr8-03008916211033353 bibr5-03008916211033353 bibr2-03008916211033353 |
| References_xml | – volume: 115 start-page: 1186 year: 2016 end-page: 1192 article-title: Patterns of response to anti-PD-1 treatment: an exploratory comparison of four radiological response criteria and associations with overall survival in metastatic melanoma patients publication-title: Br J Cancer contributor: fullname: Metser – volume: 13 issue: 2 year: 2021 article-title: Heterogeneity of response and immune system activity during treatment with nivolumab in hepatocellular carcinoma: Results from a single-institution retrospective analysis publication-title: Cancers contributor: fullname: Lanuti – volume: 8 start-page: 1581 year: 2015 end-page: 1588 article-title: Prognostic analysis of Chinese patients with metastasis renal cell cancer receiving sorafenib: results from a multicenter long-term follow-up retrospective study publication-title: Onco Targets Ther contributor: fullname: Liu – volume: 24 start-page: 978 issue: 7 year: 2018 end-page: 985 article-title: Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing publication-title: Nat Med contributor: fullname: Zheng – volume: 38 start-page: 2960 year: 2020 end-page: 2970 article-title: Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma publication-title: J Clin Oncol contributor: fullname: Zhu – volume: 57 start-page: 1407 issue: 4 year: 2013 end-page: 1415 article-title: FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma publication-title: Hepatology contributor: fullname: Matsumoto – volume: 382 start-page: 1894 year: 2020 end-page: 1905 article-title: Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma publication-title: N Engl J Med contributor: fullname: Ikeda – volume: 5 start-page: 417 year: 2017 end-page: 424 article-title: Liver metastasis and treatment outcome with anti-PD-1 monoclonal antibody in patients with melanoma and NSCLC publication-title: Cancer Immunol Res contributor: fullname: Hamid – start-page: 38 year: 2020 article-title: Different organ-specific response to nivolumab to determine the survival outcome of patients with advanced hepatocellular carcinoma (aHCC) publication-title: J Clin Oncol contributor: fullname: Cheon – volume: 8 start-page: 480 year: 2019 end-page: 490 article-title: Differential organ-specific tumor response to immune checkpoint inhibitors in hepatocellular carcinoma publication-title: Liver Cancer contributor: fullname: Shao – ident: bibr1-03008916211033353 doi: 10.1056/NEJMoa1915745 – volume: 8 start-page: 1581 year: 2015 ident: bibr10-03008916211033353 publication-title: Onco Targets Ther contributor: fullname: Guo F – start-page: 38 year: 2020 ident: bibr6-03008916211033353 publication-title: J Clin Oncol contributor: fullname: Kim HS – ident: bibr3-03008916211033353 doi: 10.1158/2326-6066.CIR-16-0325 – ident: bibr2-03008916211033353 doi: 10.1200/JCO.20.00808 – ident: bibr9-03008916211033353 doi: 10.1002/hep.25956 – ident: bibr7-03008916211033353 doi: 10.3390/cancers13020213 – ident: bibr4-03008916211033353 doi: 10.1038/bjc.2016.308 – ident: bibr5-03008916211033353 doi: 10.1159/000501275 – ident: bibr8-03008916211033353 doi: 10.1038/s41591-018-0045-3 |
| SSID | ssj0040266 |
| Score | 2.328015 |
| Snippet | Introduction:
Immune checkpoint inhibitors (ICIs) and a combination of ICIs with targeted antiangiogenic agents are effective in treatment of advanced... Immune checkpoint inhibitors (ICIs) and a combination of ICIs with targeted antiangiogenic agents are effective in treatment of advanced hepatocellular... INTRODUCTIONImmune checkpoint inhibitors (ICIs) and a combination of ICIs with targeted antiangiogenic agents are effective in treatment of advanced... |
| SourceID | proquest crossref pubmed sage |
| SourceType | Aggregation Database Index Database Publisher |
| StartPage | NP114 |
| SubjectTerms | Antibodies, Monoclonal, Humanized Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Carcinoma, Hepatocellular - diagnosis Carcinoma, Hepatocellular - drug therapy Combined Modality Therapy Disease Susceptibility Humans Liver Neoplasms - diagnosis Liver Neoplasms - drug therapy Lung Neoplasms - diagnosis Lung Neoplasms - drug therapy Lung Neoplasms - etiology Male Middle Aged Molecular Targeted Therapy Neoplasms, Second Primary - diagnosis Neoplasms, Second Primary - drug therapy Neoplasms, Second Primary - etiology Phenylurea Compounds Protein Kinase Inhibitors Quinolines Retreatment Tomography, X-Ray Computed Treatment Outcome |
| Title | Efficacy of lenvatinib plus pembrolizumab in hepatocellular carcinoma with metachronous lung metastasis: a report of two cases |
| URI | https://journals.sagepub.com/doi/full/10.1177/03008916211033353 https://www.ncbi.nlm.nih.gov/pubmed/34296632 https://search.proquest.com/docview/2555104320 |
| Volume | 107 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwvV1bS91AEB68gPjSi1Z72lpWEApCapLdnCR9KaJHfFFEW6hPYfZy8MBJcjAJYh_87Z3JpWCr0Ke-hmw2uzM7t292BmAvdmkak-vjRS4ce8oo7SGOuRahHpP695VpKX16FZ__SI4nXCanHO7C9DtYfea0KvqjVljz6eZo9EEPMh4QZ_oJGTbsvUgpI_m1qfOsC3cPXTX4CePTTc7QtuGEyHtvuN62DKtcOY-8tdXDy4ur60F4kzfVw5u-7_EMPRD65KSPVdlf9umj3LBWXZ28_O8LfQUvestWHHas-BqWXLEBa2c9dr8JDxOuVoHmXpRTQbqOY8HFTIvFvKnEwuWa-wf9bHLUYlaIG1KTdcmwAufJCsMtj4oyR8GBY5G7Gg2X9S1p7JzkVfuEDN1qVn0RKDokhCeq70oaXLnqDXw_mXw7OvX67g-ekcqvPReT9YeBIalixgZRYaBc6FvpEhvFqJNpIrV2GGmu6RjZwARWIVpH_oLB1MktWCnKwr0FMdU6UHHMbYlT5VtaqkmNtQxxymQaqBHsD4TMFl2RjywY6qD_SYER7A6kzugo8kZg4Wi5GXlnJOGUDP0RbHc88PtzkvQ-GXfhCD4xwbOB_M_P8-6f33wP6yFn2rRJNh9gpb5t3A4sV7b52LP3L93iDlw |
| link.rule.ids | 315,782,786,27927,27934,27935,44982,45370 |
| linkProvider | SAGE Publications |
| linkToHtml | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3dS9xAEB_0BNuX1o-2XlvrCoIgRJLs5pL4drQnV6oiVUGfwuzH0QMvOUyO0j70b-9MLjmwKgh9DdmP7OzOb2Zn8huAvdilaUyujxe5sOcpo7SH2GMuQt0j-PeVqSU9vIjPrpMvA6bJOWr_hWlWsDzktCqaUa2sF6ebmZIkoRbZNOy4SCkjuQwrKpKx34GV_vfzi5tWD5Nj1EQqfd_jFk1M89FO7qPSA1PzXppXjTzHr_9nzmvwqrE3RX--QdZhyeUbsHraRNQ34c-AOSTQ_BLFSBAC8Q1tPtZiejsrxdRNNFf1-T2boBbjXPwg8KoKvuzn7FVhuBBRXkxQ8HWumLgKDZPtFtT2lrRI_YTMz3JcHgkU8_gED1T9LKhx6co3cHU8uPw89JqaDJ6Ryq88F5NNhoGhs256BlFhoFzoW-kSG8Wok1EitXYYaWZajGxgAqsQrSMr3mDq5Fvo5EXutkCMtA5UHHOx4FT5lj7VpMZaDjzKZBSoLhy0Msmmc-qNLGjZyf9d0S7stlLL6IDwQmDu6HMz8plI7ygZ-l14NxfnojtJaEwmV9iFfZZd1kry6XHeP_vNHXgxvDw9yU6-nn37AC9DzoWp02A-Qqe6m7ltWC7t7FOza_8CX5zmLQ |
| linkToPdf | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3dS9xAEB_qCeKL_VSvrXULhUIhXpLdXJI-CKJ3XNGK1BbapzD7ETzwksPkKO2Df3tncknh-gGCryH7kZ3dmd_sTH4D8CZ2aRqT6-NFLhx6yijtIQ6Zi1APyfz7yjSSnlzG51-TkxHT5Bx2_8K0K1gdcFoVzahR1ny65zYftDHGAW1MPyFcw86LlDKSa7CuVJqEPVg_-nRx-a3TxeQctdFK3_e4RRvX_Gcnq5bpL7i5kurVWJ_xw_vO-xFstbhTHC03ymN44IonsPGxjaw_hdsRc0mg-SHKXJAl4pvaYqrF_HpRibmbaa7u83MxQy2mhbgiI1aXfOnPWazCcEGiopyh4GtdMXM1GibdLantNWmT5gnB0GpavRcolnEKHqj-XlLjylXP4Mt49Pl44rW1GTwjlV97LiZshoGhM2-GBlFhoFzoW-kSG8WokzyRWjuMNDMuRjYwgVWI1hGaN5g6uQ29oizcLohc60DFMRcNTpVv6VNNaqzlAKRM8kD14V0nl2y-pODIgo6l_M8V7cPrTnIZHRReCCwcfW5GvhPpHyVDvw87S5H-7k6SVSboFfbhLcsv66T5_3Ge3_nNfdi4OBlnZx_OT1_AZsgpMU02zEvo1TcLtwdrlV28ajfuLy7r6LM |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Efficacy+of+lenvatinib+plus+pembrolizumab+in+hepatocellular+carcinoma+with+metachronous+lung+metastasis%3A+a+report+of+two+cases&rft.jtitle=Tumori&rft.au=Li%2C+JieLang&rft.au=Chen%2C+Ting&rft.au=Bi%2C+Feng&rft.au=Yang%2C+Yu&rft.date=2021-12-01&rft.eissn=2038-2529&rft.volume=107&rft.issue=6&rft.spage=NP114&rft.epage=NP119&rft_id=info:doi/10.1177%2F03008916211033353&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0300-8916&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0300-8916&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0300-8916&client=summon |